## Christian Jonasson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6077849/publications.pdf

Version: 2024-02-01

24 papers 1,383 citations

623699 14 h-index 23 g-index

24 all docs 24 docs citations

times ranked

24

2899 citing authors

#	Article	IF	CITATIONS
1	Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease. JAMA - Journal of the American Medical Association, 2016, 315, 2532.	7.4	262
2	Plasma protein patterns as comprehensive indicators of health. Nature Medicine, 2019, 25, 1851-1857.	30.7	261
3	Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ: British Medical Journal, 2018, 363, k4365.	2.3	248
4	A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 28-36.	3.0	93
5	Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ: British Medical Journal, 2019, 366, 14772.	2.3	69
6	Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ, The, 2020, 369, m1186.	6.0	63
7	Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 75-85.	3.0	59
8	Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden. Lancet Diabetes and Endocrinology,the, 2019, 7, 106-114.	11.4	54
9	Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study. Diabetes Care, 2020, 43, 1326-1335.	8.6	41
10	Deciphering the Plasma Proteome of Type 2 Diabetes. Diabetes, 2020, 69, 2766-2778.	0.6	34
11	A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. Science Translational Medicine, 2022, 14, eabj9625.	12.4	31
12	Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation. Heart, 2022, 108, 345-352.	2.9	27
13	Aptamer-Based Proteomic Platform Identifies Novel Protein Predictors of Incident Heart Failure and Echocardiographic Traits. Circulation: Heart Failure, 2020, 13, e006749.	3.9	26
14	New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs. Open Heart, 2018, 5, e000931.	2.3	22
15	Metabolic syndrome and the plasma proteome: from association to causation. Cardiovascular Diabetology, 2021, 20, 111.	6.8	19
16	Plasma Proteomics of Renal Function: A Transethnic Meta-Analysis and Mendelian Randomization Study. Journal of the American Society of Nephrology: JASN, 2021, 32, 1747-1763.	6.1	16
17	Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy Complications: Cohort Study in Nationwide Registers From Two Countries. Diabetes Care, 2019, 42, e92-e94.	8.6	13
18	The comparative cardiovascular and renal effectiveness of sodiumâ€glucose coâ€transporterâ€2 inhibitors and glucagonâ€like peptideâ€l receptor agonists: A Scandinavian cohort study. Diabetes, Obesity and Metabolism, 2022, 24, 473-485.	4.4	13

#	Article	IF	CITATIONS
19	Association between adherence to concomitant proton pump inhibitor therapy in current NSAID users and upper gastrointestinal complications. European Journal of Gastroenterology and Hepatology, 2013, 25, 531-538.	1.6	9
20	Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. Diabetologia, 2021, 64, 2204-2214.	6.3	9
21	Data resource profile: Norwegian Databases for Drug Utilization and Pharmacoepidemiology. Norsk Epidemiologi, 2021, 29, .	0.3	6
22	Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. Scandinavian Journal of Gastroenterology, 2013, 48, 1010-1017.	1.5	5
23	Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Bladder and Renal Cancer: Scandinavian Cohort Study. Diabetes Care, 2022, 45, e93-e96.	8.6	3
24	Characteristics, treatment patterns, and residual cardiovascular risk of patients with a first acute myocardial infarction: A nationwide populationâ€based cohort study in Norway. Fundamental and Clinical Pharmacology, 2021, , .	1.9	0